No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy.

Martin Prøven Bogsrud, Gisle Langslet, Leiv Ose, Kjell-Erik Arnesen, Milada Cvancarova Sm Stuen, Ulrik Fredrik Malt, Berit Woldseth, Kjetil Retterstøl
{"title":"No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy.","authors":"Martin Prøven Bogsrud,&nbsp;Gisle Langslet,&nbsp;Leiv Ose,&nbsp;Kjell-Erik Arnesen,&nbsp;Milada Cvancarova Sm Stuen,&nbsp;Ulrik Fredrik Malt,&nbsp;Berit Woldseth,&nbsp;Kjetil Retterstøl","doi":"10.3109/14017431.2012.756119","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The aim of the present study was to evaluate the possible effects of Q10 and selenium supplementation on statin-induced myopathy (SIM), both for subjective symptoms and muscle function.</p><p><strong>Design: </strong>Patients (N = 43) who had experienced previous or ongoing SIM on atorvastatin therapy were recruited. Following a 6-week washout period during which no statins were administered, the patients were re-challenged with 10 mg of atorvastatin. Patients (N = 41) who experienced SIM continued the atorvastatin treatment and were in addition randomized to receive 12 weeks supplement of 400 mg Q10 and 200 μg selenium per day or a matching double placebo. SIM was assessed using 3 validated symptom questionnaires, and a muscle function test was performed at the beginning and at the end of the study.</p><p><strong>Results: </strong>The patients receiving the active supplement experienced significant increases in their serum Q10 and selenium concentrations compared with the group receiving placebo. No statistically significant differences in symptom questionnaire scores or muscle function tests were revealed between the groups.</p><p><strong>Conclusions: </strong>Despite substantial increases in the serum Q10 and selenium levels following the oral supplementation, this study revealed no significant effects on SIM compared with the placebo.</p>","PeriodicalId":137876,"journal":{"name":"Scandinavian cardiovascular journal : SCJ","volume":" ","pages":"80-7"},"PeriodicalIF":0.0000,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/14017431.2012.756119","citationCount":"44","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian cardiovascular journal : SCJ","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3109/14017431.2012.756119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/1/10 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 44

Abstract

Objective: The aim of the present study was to evaluate the possible effects of Q10 and selenium supplementation on statin-induced myopathy (SIM), both for subjective symptoms and muscle function.

Design: Patients (N = 43) who had experienced previous or ongoing SIM on atorvastatin therapy were recruited. Following a 6-week washout period during which no statins were administered, the patients were re-challenged with 10 mg of atorvastatin. Patients (N = 41) who experienced SIM continued the atorvastatin treatment and were in addition randomized to receive 12 weeks supplement of 400 mg Q10 and 200 μg selenium per day or a matching double placebo. SIM was assessed using 3 validated symptom questionnaires, and a muscle function test was performed at the beginning and at the end of the study.

Results: The patients receiving the active supplement experienced significant increases in their serum Q10 and selenium concentrations compared with the group receiving placebo. No statistically significant differences in symptom questionnaire scores or muscle function tests were revealed between the groups.

Conclusions: Despite substantial increases in the serum Q10 and selenium levels following the oral supplementation, this study revealed no significant effects on SIM compared with the placebo.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
辅酶Q10和硒联合补充对阿托伐他汀诱导的肌病无影响。
目的:本研究的目的是评估辅酶Q10和硒补充剂对他汀类药物诱导的肌病(SIM)的可能影响,包括主观症状和肌肉功能。设计:招募之前或正在接受阿托伐他汀治疗的患者(N = 43)。在没有他汀类药物的6周洗脱期后,患者再次接受10mg阿托伐他汀治疗。接受SIM治疗的患者(N = 41)继续接受阿托伐他汀治疗,并随机接受每天400 mg辅酶Q10和200 μg硒的12周补充或匹配的双重安慰剂。使用3份经过验证的症状问卷评估SIM,并在研究开始和结束时进行肌肉功能测试。结果:与安慰剂组相比,接受活性补充剂的患者血清辅酶Q10和硒浓度显著增加。两组间症状问卷评分和肌肉功能测试均无统计学差异。结论:尽管口服补充剂后血清辅酶Q10和硒水平显著增加,但本研究显示与安慰剂相比,对SIM没有显著影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Hyperglycemia-simulating environment attenuated experimentally induced calcification in cultured human aortic valve interstitial cells. Outcomes of descending and thoracoabdominal aortic repair in connective tissue disorder patients. The a' velocity by tissue-Doppler echocardiography correlates to invasive mean left atrial pressure in patients with normal ejection fraction. Long-term prognosis after a first myocardial infarction: eight years follow up of the case-control study PAROKRANK. Percutaneous balloon pericardiotomy: efficacy in a series of malignant and nonmalignant cases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1